STOCK TITAN

Onconetix, Inc. - $ONCO STOCK NEWS

Welcome to our dedicated page for Onconetix news (Ticker: $ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Onconetix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Onconetix's position in the market.

Rhea-AI Summary
Onconetix, Inc. (ONCO) appoints Dr. Ajit Singh and Dr. Thomas Meier to its Board of Directors. Dr. Singh brings vast experience from Silicon Valley and Dr. Meier has a strong background in biotechnology. Both experts are set to enhance Onconetix's growth in oncology therapeutics and diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
Onconetix, Inc.

Nasdaq:ONCO

ONCO Rankings

ONCO Stock Data

2.58M
21.70M
22%
18.63%
2.36%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CINCINNATI

About ONCO

developed by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in variability. these regions of the virus were shown in thompson et al 2018 to direct the antigenic evolution of the influenza virus and therefore make ideal vaccine targets. the vaccine thus negates the need for (i) annual vaccination, providing potentially life-long protection against flu, and (ii) reformulation of the vaccine every few years.